Trulieve Reports Mixed Q2 2026 Results Amid Strategic Shifts — Trulieve Cannabis Corp.

Event summary

Trulieve reported Q2 2026 revenue of $271 million, down 10% YoY, with a gross margin of 60%.
The company recorded a net loss attributable to common shareholders of $406 million, primarily due to a $407 million impact from the Harvest deconsolidation.
Trulieve achieved adjusted EBITDA of $98 million, or 36% of revenue, and generated cash flow from operations of $53 million.
The company listed on the New York Stock Exchange under the ticker 'TRLV' following federal rescheduling of medical marijuana to Schedule III.

The big picture

Trulieve's Q2 2026 results reflect the challenges of strategic shifts amid a changing regulatory landscape. The company's listing on the NYSE marks a significant milestone following federal rescheduling, positioning it to capitalize on broader cannabis market opportunities. However, revenue declines and high operating expenses highlight the need for continued operational efficiency as Trulieve navigates its next phase of growth.

What we're watching

Regulatory Tailwinds: How federal rescheduling and state program expansions in markets like Georgia and Texas will impact Trulieve's growth trajectory.
Financial Stability: Whether Trulieve can sustain its adjusted EBITDA margin and positive cash flow amid revenue declines.
Strategic Execution: The pace at which Trulieve can leverage its scale, financial strength, and branded products to drive future growth post-Harvest deconsolidation.